NSE filing, NSE: GLAND. Summary written from the filing by ALFA Finder's alert engine.
Gland Pharma Ltd: key numbers
- Share price
- ₹3,043.00
- Market cap
- ₹50,213 Cr
- Revenue (annual)
- ₹6,431 Cr
- Net profit (annual)
- ₹1,027 Cr
- P/E (TTM)
- 44.5×Sector 46.5×
- Promoter holding
- 45.75%-6.02% QoQ
- FII holding
- 10.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gland Pharma Ltd
All →Gland Pharma Business Update
Gland Pharma reports that USFDA concluded an unannounced cGMP inspection at its Dundigal formulation facility with four procedural Form 483 observations. No monetary impact is stated, and corrective actions will be submitted within the stipulated period.
Gland Pharma Board Meeting Date
Gland Pharma Ltd scheduled a board meeting for November 06, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ending September 30, 2026.
Gland Pharma Other Announcement
Gland Pharma Limited has filed the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026.
Gland Pharma Management Change
Gland Pharma Limited announced the resignation of director Wenjie Zhang and the appointment of Xingli Wang as a Non-Executive Non-Independent Director effective October 1, 2026.
Gland Pharma Acquisition Worth ₹199.5 Cr
Gland Pharma Limited's board approved a USD 21 million investment in its subsidiary, Gland USA, to acquire a 60% stake in Novelstar Pharma Inc. This acquisition facilitates business expansion in the USA.
- Value
- ₹199.5 Cr
- Execution
- By October 31, 2026
Gland Pharma Promoter Selling
Fosun Pharma Industrial Pte. Ltd. sold 98,97,000 shares of Gland Pharma Ltd via open market transactions. This reduced their stake from 51.76% to 45.76%.
- Promoter stake change
- -6.00%
Other annual general meeting announcements
All →Unihealth Hospitals Annual General Meeting
Unihealth Hospitals reported postal ballot results: all three resolutions passed, covering a related-party loan-to-equity conversion with UMC Hospitals, variation of unutilised IPO proceeds, and migration from NSE Emerge to the main board. No rupee amount is stated for the approvals.
Vedanta Iron and Steel Annual General Meeting
Vedanta Iron and Steel seeks shareholder approval via postal ballot for seven material related party transaction resolutions. E-voting runs from 29 October to 27 November 2026.
GTPL Hathway Annual General Meeting
GTPL Hathway seeks shareholder approval by postal ballot to appoint Gurjeev Singh Kapoor as Non-Executive Director. E-voting runs November 1 to 30, 2026.
HEG Advanced Materials Annual General Meeting
HEG Advanced Materials seeks approval via postal ballot to appoint seven directors and fix MD Riju Jhunjhunwala's remuneration. E-voting runs October 29 to November 27, 2026.
Trident Texofab Annual General Meeting
Trident Texofab's EGM on 28 October 2026 sought approval for a statutory auditor to fill a casual vacancy. Only one ordinary resolution was tabled.
Sonaselection India Annual General Meeting
Sonaselection India's AGM on 25 Sep 2026 passed all three ordinary resolutions, including adoption of FY2026 audited accounts. Each resolution received 100% of votes polled in favour, with 88.43% of outstanding shares voting.